Daiichi Pharmaceutical
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Enhertu | Trastuzumab deruxtecan | 2019-12-20 | ||
| Floxin | Ofloxacin | 1997-12-16 | ||
| Lixiana | Edoxaban | 2015-06-19 | 2027-2028 | |
| Nilemdo | Bempedoic acid | 2020-04-01 | 2025-2040 | |
| Nustendi | Bempedoic acid, Ezetimibe | 2020-03-27 | 2025-2040 | |
| Savaysa | Edoxaban | 2015-01-08 | 2027-2028 | |
| Turalio | Pexidartinib | 2019-08-02 | 2027-2038 | |
| Vanflyta | Quizartinib | 2023-07-20 | 2027-2033 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
9
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use